Franklin Resources Inc. Makes New Investment in MaxCyte, Inc. (NASDAQ:MXCT)

Franklin Resources Inc. acquired a new stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 67,249 shares of the company’s stock, valued at approximately $260,000. Franklin Resources Inc. owned about 0.06% of MaxCyte as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. Intech Investment Management LLC acquired a new stake in MaxCyte during the 3rd quarter valued at approximately $51,000. China Universal Asset Management Co. Ltd. lifted its holdings in MaxCyte by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock worth $79,000 after buying an additional 7,930 shares in the last quarter. Verition Fund Management LLC raised its holdings in shares of MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock valued at $83,000 after purchasing an additional 6,045 shares in the last quarter. Creative Planning boosted its position in shares of MaxCyte by 33.6% during the 3rd quarter. Creative Planning now owns 28,652 shares of the company’s stock worth $111,000 after acquiring an additional 7,212 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in MaxCyte by 22.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock valued at $128,000 after purchasing an additional 5,927 shares during the last quarter. 68.81% of the stock is owned by institutional investors.

MaxCyte Price Performance

Shares of MaxCyte stock opened at $4.16 on Thursday. The firm’s fifty day simple moving average is $3.79 and its 200-day simple moving average is $4.01. The stock has a market capitalization of $439.67 million, a price-to-earnings ratio of -12.23 and a beta of 1.37. MaxCyte, Inc. has a 12 month low of $3.16 and a 12 month high of $5.55.

MaxCyte (NASDAQ:MXCT) last released its earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The business had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7.50 million. During the same period last year, the business earned ($0.11) earnings per share. Analysts anticipate that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.